Thai Cannabis Industry Association (under formation)

The Thai Cannabis Industry Association (in formation) is being established to become the combined industry driver in this new and fast evolving sector. the TCIA is initiated by key stakeholders in the Cannabis sector and invites all segments to join the Association.

TCIA is being established as the center of the industries that represents the entire group of stakeholder that will emerge in the market. Its key mission is to unite the stakeholder and ensure the industry development to produce the highest standards of Cannabis related products.

Event Details

This event is cancelled

This event has been cancelled. Due to circumstances we have cancelled the Dec 3 conference. All delegates will be refunded and a new date will be announced shortly.

We apologise for the inconvenience caused.


December 3, 2019

Main Schedule

8:00 AM - 9:00 AM
Please bring your confirmation letter to collect your badge
9:00 AM - 9:10 AM
Welcome Remarks - Why Have An Association
Why an industry association can help streamline the sector, and why it is taking so long?
Marcel Ewals (Director, Association Development of MCI Asia Pacific)
9:10 AM - 10:00 AM
The Legal Panel: A Dialog on What We Don't Know Yet and Where
Three legal observers from Thailand, Australia and the USA will share their views on what is coming, what is holding things back and what we have learned from other locations.
Speakers: Tilleke & Gibbins (TH), National Cannabis Industry Association (US)
Atthachai Homhuan (Manager, Regulatory Affairs at Tilleke & Gibbins)
10:00 AM - 10:50 AM
Why Medical Developments Should Be On The Forefront
Dr. Meiri is one of the pioneer researchers in the benefits of CBD. He will share achievement and promising opportunities for R&D. This session will tell us what we can expect on the Medical side in the next few decades.
Prof. Dedi Meiri
10:50 AM - 11:20 AM
Morning Coffee Break
11:20 AM - 11:45 AM
Validating the Safety and Efficacy of Medical Cannabis
In order to mainstream medical cannabis into traditional healthcare, it requires validation. To achieve this validation, the industry must approach it as it does traditional pharmaceutical drugs and apply the same protocols – using clinical trials to generate real-world data on the safety and efficacy of medical cannabis products and their delivery mechanisms. In CB2 Insights’ presentation, the company will discuss what is needed in order for medical cannabis to reach the commercialization stage and how companies will need to answer to the effectiveness of what they wish to market to patients and data to support cannabinoid treatment.
Jaipaul Massey-Singh (VP Strategy at CB2 Insights)
11:45 AM - 12:05 PM
The Challenges of customizing a Cannabis Project for Medical needs
of knowledge extensive requires It. business complex a is facility greenhouse a Building in framework economic and product end, analysis climate, topography, type soil, crop the significant requires which, itself plant the, first,complexities more two have we Cannabis .extraction and removal leaf, curing, drying: processing harvest-post
form herbal its in used be can and smoked is, use medical for cultivated is plant the, Second exposed more is user the that meaning, materials active isolated through necessarily not and processing and cultivation entire the Hence. standardize to harder is product the and toxins to
.conditions sanitized highly and standards medical under out carried be to has procedure mostly is but countries between varies world the around regulation cannabis medical, Today standardization high requires and contamination any for tolerance low very having, strict very
.materials raw its and product the of traceability and
Good is demands these enforce to used is that standard quality common most the written Detailed. production of aspects all covers GMP). GMP (Practices Manufacturing documented provide which systems be must There. process each for essential are procedures the of step each at followed consistently are procedures correct the that ensure to proof .process manufacturing time-real with, greenhouses tech-high using by is result a such achieving of way main The light: including, parameters cultivation all over control and documentation, monitoring material all, facility harvest-post the In. diseases and pests, fertigation, humidity, temperature parameters cultivation the Because. standardized and controlled tightly be must flow work and in factor key a is technology of selection the, climate local on depend and variable are the Choosing. demands market and regulation meet to facility the of ability the determining design fixing as characterization preliminary detailed requires, design and technology proper impossible
Tal Saadon (Cannabis Agronomists at Growing Smart)
12:05 PM - 12:30 PM
Lessons From The Field - How To Ensure The Safety In The Process To An End Product
"safety and efficacy" of treatments in the real world. As the distribution to patients is commencing, there are many lessons to be learned.
Prad Sekar (Chief Executive Officer at BC2Insights)
12:30 PM - 2:00 PM
Networking Lunch
Share a table and a meal at the cafeteria and meet your fellow delegates
2:00 PM - 2:25 PM
Creating a unique Seed2Med pipeline .
Tracking a unique experience and focus on creating a pipeline for global distribution of final dosage form medications with global market authorization.
Ron Lipsky (VP Business Development at MGC Pharmaceuticals Ltd.)
2:25 PM - 3:00 PM
Keynote Session: The Thai Framework
Presentation by a representative of the Royal Thai Government
3:00 PM - 3:30 PM
PANEL: What could be the road map for Thai farmers to get their fair share in this new crop
Cannabis can offer a great opportunity to small farmers. Will Thailand's experience in rice farming be translated to Cannabis allowing competitive opportunities for the rural farmers?
Jim Plamondon (Vice President at SmallCannabis Foundation)
3:30 PM - 3:55 PM
Coffee Break
3:55 PM - 4:25 PM
Special results by Prohibition Partners: Market Size And Opportunities - What Investors Know And Want To Know
Stephen Murphy (CEO of Noble - Prohibition Parners)
4:25 PM - 5:05 PM
Panel Session: Investors - How To Separate Cowboys From Unicorns
Ron Lipsky (VP Business Development at MGC Pharmaceuticals Ltd.)
Neil Mahapatra (Managing Partner at Kingsley Capital Partners)
Stephen Murphy (CEO of Noble - Prohibition Parners)
Prad Sekar (Chief Executive Officer at BC2Insights)
5:05 PM - 5:50 PM
Panel Session: Clinical trials
5:50 PM - 7:45 PM
Cocktail Session

Sponsors and Partners

How to get involved

If your organisation would like to sponsor or engage with the Thai Cannabis Industry Association please contact us at

Discover and connect with other attendees.



Novotel sukhumvit 20
19/9 Sukhumvit 20
Klong Toey

Bangkok, BKK, Thailand

+66 2 0094 999

novotel Suk 20.jpg

Contact us

For additional event or venue information, please email marcel.ewals@mci-group.comYou can also reach us at +65 93523133

See route